摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

o-Xylene; compound with trichloro-methane | 7285-22-5

中文名称
——
中文别名
——
英文名称
o-Xylene; compound with trichloro-methane
英文别名
Chloroform;1,2-xylene
o-Xylene; compound with trichloro-methane化学式
CAS
7285-22-5
化学式
CHCl3*C8H10
mdl
——
分子量
225.545
InChiKey
ROUGRICPWDOYIK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.29
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    0

文献信息

  • Pesticide composition
    申请人:CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT.
    公开号:EP0317433A1
    公开(公告)日:1989-05-24
    The present invention relates to a multi-component pesticidal composition against arthropoda containing as active ingredient pyrethroides and phosphate esters and optionally piperonyl butoxide and excipients com­prising as pyrethroid component 0.1 to 40 percent by weight of cypermethrin related to the total weight comprising out of the 8 possible isomers 40 to 100 per­cent by weight of 1RcisS and/or 1RtransS stereoisomer and as a second component at least one phosphoric acid, thiophosphoric acid or dithiophosphate being toxic on arthropoda at a ratio of 1:1-99 related to the amount of cypermethrin.
    本发明涉及一种针对节肢动物的多组分杀虫组合物,该组合物含有作为活性成分的拟除虫菊酯磷酸酯以及可选的胡椒基丁醚和赋形剂,其中拟除虫菊酯成分占总重量的 0.1%至40%(以总重量计)的氯氰菊酯,其中包括8种可能的异构体中40%至100%(以总重量计)的1RcisS和/或1RtransS立体异构体,以及作为第二组分的至少一种对节肢动物有毒的磷酸硫代磷酸二硫代磷酸,与氯氰菊酯的用量之比为1:1-99。
  • CYCLIC POLYPHENYLENE ETHER ETHER KETONE COMPOSITION AND METHOD FOR PRODUCING THE SAME
    申请人:Toray Industries, Inc.
    公开号:EP2508518A1
    公开(公告)日:2012-10-10
    The present invention provides a cyclic poly (phenylene ether ether ketone) composition comprising not less than 60% by weight of a cyclic poly (phenylene ether ether ketone) represented by the following Formula (I), which is characterized in that the cyclic poly (phenylene ether ether ketone) is a mixture of cyclic poly (phenylene ether ether ketone)s having different repeating numbers (m) and the composition has a melting point of not higher than 270°C; and a method of producing a poly (phenylene ether ether ketone) characterized by heat-polymerizing the cyclic poly (phenylene ether ether ketone) composition: (wherein, m represents an integer of 2 to 40).
    本发明提供了一种环状聚(亚苯基醚醚酮)组合物,该组合物包含不少于60%(重量)由下式(I)表示的环状聚(亚苯基醚醚酮),其特征在于环状聚(亚苯基醚醚酮)是具有不同重复数(m)的环状聚(亚苯基醚醚酮)的混合物,且该组合物的熔点不高于270℃;以及一种生产聚(亚苯基醚醚酮)的方法,其特征在于对环状聚(亚苯基醚醚酮)组合物进行热聚合: (其中,m 代表 2 至 40 的整数)。
  • Medical device with coating that promotes endothelial cell adherence
    申请人:——
    公开号:US20020049495A1
    公开(公告)日:2002-04-25
    This invention provides compositions and methods for producing a medical device coated with a matrix and an antibody which reacts with an endothelial cell antigen. The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin, amorphous carbon. In a third embodiment, the matrix may be composed of fullerenes. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote adherence of endothelial cells on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following adherence to the medical device, the endothelial cells differentiate and proliferate on the medical device. The antibodies may be different types of monoclonal antibodies. Methods of preparing such composition and methods of treating a mammal with atherosclerosis or other types of vessel obstruction are disclosed. By facilitating adherence of endothelial cells to the surface of the medical device, the methods and compositions of this invention will decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.
    本发明提供了生产涂有基质和与内皮细胞抗原反应的抗体的医疗器械的组合物和方法。包覆医疗器械的基质可由合成材料组成,如聚酯、聚左旋乳酸纤维素酯或聚乙二醇。在另一个实施方案中,基质由天然材料组成,如胶原蛋白纤维蛋白弹性蛋白、无定形碳。在第三个实施方案中,基质可由富勒烯组成。富勒烯的范围从约 C60 到约 C100。医疗设备可以是支架或合成移植物。抗体可促进内皮细胞附着在医疗设备上。抗体可与基质混合,或通过连接分子与基质共价连接。粘附到医疗设备后,内皮细胞会在医疗设备上分化和增殖。抗体可以是不同类型的单克隆抗体。本文公开了制备这种组合物的方法以及治疗患有动脉粥样硬化或其他类型血管阻塞的哺乳动物的方法。通过促进内皮细胞附着在医疗器械表面,本发明的方法和组合物将降低再狭窄的发生率以及因植入医疗器械而引起的其他血栓栓塞并发症。
  • Organic electroluminescent device
    申请人:Li Jian
    公开号:US20050238915A1
    公开(公告)日:2005-10-27
    An organic electroluminescent device comprising a light emitting layer disposed between a pair of electrodes, wherein the light emitting layer contains a light emitting material, and a host polymer having a first unit interacting with the light emitting material so that energy can be transferred to the light emitting material, and a second unit having a conjugated or non-conjugated structure.
    一种有机电致发光器件,包括设置在一对电极之间的发光层,其中发光层包含发光材料和宿主聚合物,宿主聚合物具有与发光材料相互作用的第一单元,以便将能量传递给发光材料,以及具有共轭或非共轭结构的第二单元。
  • COATING WHICH PROMOTES ENDOTHELIAL CELL ADHERENCE
    申请人:OrbusNeich Medical, Inc.
    公开号:EP1263484B1
    公开(公告)日:2007-05-16
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫